Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing-Remitting MS.

Annals of clinical and translational neurology·2026
Same author

Plasma pTau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease.

medRxiv : the preprint server for health sciences·2026
Same author

Distinct mechanistic pathways of early tauopathy revealed by <i>MAPT</i> mutations.

bioRxiv : the preprint server for biology·2026
Same author

Brain injury biomarkers and intraoperative hypotension: associations with pituitary hormone deficiency following transsphenoidal endoscopic surgery for non-functioning pituitary adenomas.

Pituitary·2025
Same author

The impact of cardiorespiratory fitness on Alzheimer's disease biomarkers and their relationships with cognitive decline.

medRxiv : the preprint server for health sciences·2025
Same author

The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use.

Multiple sclerosis and related disorders·2025

Related Experiment Video

Updated: May 2, 2026

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.3K

Assessing tissue damage in multiple sclerosis: a biomarker approach.

J Burman1, H Zetterberg, M Fransson

  • 1Department of Neuroscience, Uppsala University, Uppsala, Sweden; Department of Neurology, Uppsala University Hospital, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Acta Neurologica Scandinavica
|February 28, 2014
PubMed
Summary

Biomarkers for oligodendrocyte, axonal, and astrocyte injury, including myelin basic protein (MBP) and neurofilament light (NFL), can now directly measure tissue damage in multiple sclerosis (MS). This aids in assessing disease activity beyond MRI scans.

Keywords:
glial fibrillary acidic proteinmagnetic resonance imagingmultiple sclerosismyelin basic proteinneurofilament

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K

Related Experiment Videos

Last Updated: May 2, 2026

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.3K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Clinical Neurology

Background:

  • Magnetic resonance imaging (MRI) is standard for multiple sclerosis (MS) disease activity assessment.
  • MRI effectively shows accumulated damage but not ongoing tissue injury.

Purpose of the Study:

  • To correlate biomarkers of oligodendrocyte, axonal, and astrocyte injury with MRI and clinical findings in MS.
  • To evaluate tissue damage in MS using these biomarkers.

Main Methods:

  • Cerebrospinal fluid from 44 relapsing-remitting MS, 20 secondary progressive MS patients, and 15 controls was analyzed for myelin basic protein (MBP), neurofilament light (NFL), and glial fibrillary acidic protein (GFAp) using ELISA.
  • Patients underwent brain and spinal cord MRI, with counts of gadolinium-enhancing, T1, and T2 lesions.

Main Results:

  • Elevated MBP and NFL levels in patients during relapse or with asymptomatic gadolinium-enhancing lesions indicated ongoing oligodendrocyte and axonal damage.
  • MBP levels decreased rapidly post-relapse, NFL remained elevated for weeks, and GFAp increased slowly.
  • MS patients without active lesions showed biomarker levels similar to controls, while secondary progressive MS patients had moderately elevated levels.

Conclusions:

  • Analysis of MBP, NFL, and GFAp provides direct measurement of tissue damage in MS.
  • These biomarkers are a valuable addition to current methods for evaluating MS progression and activity.